Evidence map›Paper›PMID 27870250›Full record

ArticleProtein science : a publication of the Protein Society2017

New insights into interactions between the nucleotide-binding domain of CFTR and keratin 8.

Aiswarya Premchandar, Anna Kupniewska, Arkadiusz Bonna, Grazyna Faure, Tomasz Fraczyk, Ariel Roldan, Brice Hoffmann, Mélanie Faria da Cunha, Harald Herrmann, Gergely L Lukacs and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Recent Strategic Advances in CFTR Drug Discovery: An Overview.International journal of molecular sciences · 2020
    Review
  5. CK19 stabilizes CFTR at the cell surface by limiting its endocytic pathway degradation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 5 countries.

Aiswarya PremchandarInstitute of Biochemistry and Biophysics, Polish Academy of Sciences, Poland.
Anna KupniewskaINSERM U1151, team Canalopathies épithéliales : la mucoviscidose et autres maladies, Université Paris Descartes, Paris, France.
Arkadiusz BonnaInstitute of Biochemistry and Biophysics, Polish Academy of Sciences, Poland.
Grazyna FaureUnité Récepteurs-Canaux; Institut Pasteur, CNRS, URA 2182, Paris, F-75015, France.
Tomasz FraczykInstitute of Biochemistry and Biophysics, Polish Academy of Sciences, Poland.
Ariel RoldanDepartment of Physiology, McGill University, Montreal, QC, Canada.
Brice HoffmannIMPMC, Sorbonne Universités, UPMC Université Paris 06, UMR CNRS 7590, Museum National d'Histoire Naturelle, IRD UMR 206, IUC, Paris Cedex 05, 75005, France.
Mélanie Faria da CunhaINSERM U1151, team Canalopathies épithéliales : la mucoviscidose et autres maladies, Université Paris Descartes, Paris, France.
Harald HerrmannDepartment of Molecular Genetics, German Cancer Research Center, Heidelberg, D-69120, Germany.
Gergely L LukacsDepartment of Physiology, McGill University, Montreal, QC, Canada.
Aleksander EdelmanINSERM U1151, team Canalopathies épithéliales : la mucoviscidose et autres maladies, Université Paris Descartes, Paris, France.
Michał DadlezInstitute of Biochemistry and Biophysics, Polish Academy of Sciences, Poland.
Délégation Paris 5 · FRInstitute of Biochemistry and Biophysics, Polish Academy of Sciences · PLCentre National de la Recherche Scientifique · FRMcGill University · CAGerman Cancer Research Center · DEUniversity of Cambridge · GB

Funding

Correction of defective functional expression of CFTR in cystic fibrosisR01DK075302 · NIDDK · MCGILL UNIVERSITY · PI LUKACS, GERGELY L. · 2006 to 2020
$3.3M
CIHRNIDDK NIH HHS R01 DK075302
6 · The paper itself

Abstract

The intermediate filament protein keratin 8 (K8) interacts with the nucleotide-binding domain 1 (NBD1) of the cystic fibrosis (CF) transmembrane regulator (CFTR) with phenylalanine 508 deletion (ΔF508), and this interaction hampers the biogenesis of functional ΔF508-CFTR and its insertion into the plasma membrane. Interruption of this interaction may constitute a new therapeutic target for CF patients bearing the ΔF508 mutation. Here, we aimed to determine the binding surface between these two proteins, to facilitate the design of the interaction inhibitors. To identify the NBD1 fragments perturbed by the ΔF508 mutation, we used hydrogen-deuterium exchange coupled with mass spectrometry (HDX-MS) on recombinant wild-type (wt) NBD1 and ΔF508-NBD1 of CFTR. We then performed the same analysis in the presence of a peptide from the K8 head domain, and extended this investigation using bioinformatics procedures and surface plasmon resonance, which revealed regions affected by the peptide binding in both wt-NBD1 and ΔF508-NBD1. Finally, we performed HDX-MS analysis of the NBD1 molecules and full-length K8, revealing hydrogen-bonding network changes accompanying complex formation. In conclusion, we have localized a region in the head segment of K8 that participates in its binding to NBD1. Our data also confirm the stronger binding of K8 to ΔF508-NBD1, which is supported by an additional binding site located in the vicinity of the ΔF508 mutation in NBD1.

Indexed as

Cystic Fibrosis Transmembrane Conductance RegulatorDeuterium Exchange MeasurementHumansKeratin-8PeptidesProtein DomainsCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorKeratin-8KRT8 protein, humanPeptidesCFTRcystic fibrosishydrogen-deuterium exchange mass spectrometrykeratin 8NBD1protein structure

Identifiers

PMID27870250
PMCPMC5275743
OpenAlexW2552391442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.